Patents for A61P 35 - Antineoplastic agents (221,099)
09/2011
09/29/2011US20110236362 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM
09/29/2011US20110236354 Symbiotic bacterial oncolysis-a beacon-based method for enhanced destruction of solid tumors-including both the tumor core and rim
09/29/2011US20110236352 PEGylation by the Dock and Lock (DNL) Technique
09/29/2011US20110236345 Composition and methods for eliciting an immune response
09/29/2011US20110236344 Synthetic mimics of mammalian cell surface receptors: method and compositions
09/29/2011US20110236325 Methods to treat or prevent a skin condition using a nell1 peptide
09/29/2011US20110236317 Tetrahydrotriazine compounds for treating diseases associated with ampk acitivity
09/29/2011US20110236314 Method of detection and diagnosis of oral and nasopharyngeal cancers
09/29/2011US20110236312 Nucleoside analogues useful as positron emission tomography (pet) imaging agents
09/29/2011US20110236311 Radiolabelling methods
09/29/2011US20110236305 Methods for protecting and regenerating bone marrow using cxcr3 agonists and antagonists
09/29/2011US20110236304 Structural variants of antibodies for improved therapeutic characteristics
09/29/2011CA2794266A1 Compositions and methods for glucose transport inhibition
09/29/2011CA2794211A1 Benzonaphthyridinamines as autotaxin inhibitors
09/29/2011CA2794153A1 Chemical compounds
09/29/2011CA2794086A1 Heterocyclic compounds useful for kinase inhibition
09/29/2011CA2793753A1 Antibodies to muc16 and methods of use thereof
09/29/2011CA2793750A1 Method and compositions to induce apoptosis of tumoral cells expressing shh
09/29/2011CA2793536A1 Methods of treatment of hepatocellular carcinoma
09/29/2011CA2792276A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
09/29/2011CA2791991A1 Anti-lrp6 antibodies
09/29/2011CA2789778A1 Cyclopentyl - and cycloheptylpyrazoles as fxr modulators
09/29/2011CA2789200A1 Pharmaceutically active disubstituted triazine derivatives
09/29/2011CA2789074A1 Bispecific antibodies
09/28/2011EP2368910A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
09/28/2011EP2368906A1 Fas associated factor 1
09/28/2011EP2368902A2 Insulin and IGF-1 receptor agonists and antagonists
09/28/2011EP2368898A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals
09/28/2011EP2368895A1 Ferrocenyl flavonoids
09/28/2011EP2368889A1 Inhibitors of tyrosine kinases
09/28/2011EP2368885A1 Derivatives of phenazine useful to treat cancer
09/28/2011EP2368876A1 Derivatives of aminoindanes, their preparation and their application in therapeutics
09/28/2011EP2368577A2 Methods for treating interleukin-6 related diseases
09/28/2011EP2368575A2 Dry formulation for transcutaneous immunization
09/28/2011EP2368566A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy
09/28/2011EP2368564A1 Pharmaceutical composition for acute phase protein targeted treatment of acute and chronic dysregulated inflammatory diseases or conditions
09/28/2011EP2368551A2 Methods of use for cyclopamine analogs
09/28/2011EP2368431A1 Immunostimulatory G,U-containing oligoribonucleotides
09/28/2011EP2367939A1 Methods for diagnosing or treating prostate cancer
09/28/2011EP2367830A1 1-oxa-8-azaspiro [4, 5] decane- 8 -carboxamide compounds as faah inhibitors
09/28/2011EP2367829A1 Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
09/28/2011EP2367827A1 3-(3-pyrimidine-2-yl-benzyl)-ý1,2,4¨triazolo ý4,3-b¨pyridazine derivatives
09/28/2011EP2367821A1 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
09/28/2011EP2367815A1 Pyridazinone derivatives
09/28/2011EP2367809A1 Derivatives of ý(3-hydroxy-4 pyron-2-yl)methyl¨-amine and use thereof as anti-neoplastic drugs
09/28/2011EP2367800A2 New compounds
09/28/2011EP2367784A1 Bicyclic triterpenoid iripallidal as a novel antiglioma and antineoplastic therapy in vitro
09/28/2011EP2367565A1 Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
09/28/2011EP2367564A1 Norrin in the treatment of diseases associated with an increased tgf-beta activity
09/28/2011EP2367560A1 Anti-cancer nutraceutical composition
09/28/2011EP2367545A1 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
09/28/2011EP2367425A1 Combinations and modes of administration of therapeutic agents and combination therapy
09/28/2011EP2133335B1 Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor
09/28/2011EP1926722B1 Substituted benzimidazoles as kinase inhibitors
09/28/2011EP1912972B1 Substituted imidazole compounds as ksp inhibitors
09/28/2011EP1864131B1 Natural ligand of g protein coupled receptor rcc356 and uses thereof
09/28/2011EP1845990B1 Treatment of metastasized tumors
09/28/2011EP1806132B1 Stat3 phosphorylation inhibitor and notch1 expression inhibitor
09/28/2011EP1741716B1 Process for producing pentacyclic taxane
09/28/2011EP1572134B1 Protein s for use as a neuroprotective agent
09/28/2011EP1426054B1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
09/28/2011EP1424330B1 Activator for peroxisome proliferator-responsive receptor delta
09/28/2011EP1420809B1 Use of cyclopenta[g]quinazoline derivatives for treating cancer
09/28/2011EP1420800B1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity
09/28/2011EP1322307B1 Methods for treating cell proliferative disorders and viral infections
09/28/2011EP1237891B1 Heterocyclic dihydropyrimidines as potassium channel inhibitors
09/28/2011CN201990619U 一种香菇多糖的提取、分离纯化及浓缩装置 An extract lentinan, purification and concentration device
09/28/2011CN201987908U 一次性中药外敷贴膜 Disposable foil TCM herbs
09/28/2011CN1980661B Cationic bacteriochlorophyll derivatives and uses thereof
09/28/2011CN1905899B EphA2 agonistic monoclonal antibodies and methods of use thereof
09/28/2011CN1897951B Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
09/28/2011CN1826059B Composition containing lactic acid bacterium producing equol
09/28/2011CN1543356B Anti-tumor agent
09/28/2011CN1344159B Combinations for treatment of diseases involving angiogenesis
09/28/2011CN102203291A Tbc1d7 as tumor marker and therapeutic target for cancer
09/28/2011CN102203290A Molecular marker for cancer stem cell
09/28/2011CN102203283A Methods for the cytological analysis of cervical cells
09/28/2011CN102203255A RNA antagonists targeting HSP27
09/28/2011CN102203250A Syngr4 for target genes of cancer therapy and diagnosis
09/28/2011CN102203118A Peptide antagonist of interleukin-15 activity
09/28/2011CN102203112A Certain chemical entities, compositions, and methods
09/28/2011CN102203110A Trehalose compound, method for producing same, and pharmaceutical product containing the compound
09/28/2011CN102203098A Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors
09/28/2011CN102203096A Compounds that expand hematopoietic stem cells
09/28/2011CN102203095A Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
09/28/2011CN102203093A Aminotriazolopyridines and their use as kinase inhibitors
09/28/2011CN102203092A Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
09/28/2011CN102203088A Poly-heteroaryl derivatives for the treatment of cancer
09/28/2011CN102203085A Processes for the preparation of crystalline forms of sunitinib malate
09/28/2011CN102203084A Nilotinib hci crystalline forms
09/28/2011CN102203083A Compounds and compositions as kinase inhibitors
09/28/2011CN102203079A Picolinamide derivatives as kinase inhibitors
09/28/2011CN102203063A Carbazole compounds and therapeutic uses of the compounds
09/28/2011CN102203061A Selective seprase inhibitors
09/28/2011CN102203056A Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof
09/28/2011CN102202737A Disubstituted phthalazine hedgehog pathway antagonists
09/28/2011CN102202693A Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
09/28/2011CN102202668A Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
09/28/2011CN102202667A Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
09/28/2011CN102202663A Parenteral and oral formulations of benzimidazoles